HOTAMISLIGIL GKHAN S,BURAK MEHMET F,Engin Feyza,WIDENMAIER SCOTT B,ROBERTS ELISABETH HELEN,MOORE ADRIAN RICHARD,DOYLE CARL BRENDAN,ADAMS RALPH,HERV KARINE JEANNINE MADELEINE,WALES SHAUNA MHAIRI,TYSON
申请号：
IN201717042934
公开号：
IN201717042934A
申请日:
2017.11.30
申请国别(地区):
IN
年份:
2018
代理人:
摘要：
This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as aP2) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
